Title: A systematic review of Nipah virus disease epidemiological parameters, outbreaks and mathematical models

Authors: Tristan Naidoo[1,*], Christian Morgenstern[1,2,*], Patrick Doohan[1], Rhys Earl[1], Thomas Rawson[3], Richard J Sheppard[1], Joseph T Hicks[1], Sreejith Radhakrishnan[1], Rob Johnson[1], Anna-Maria Hartner[1,4], Lorenzo Cattarino[1], Kelly McCain[1], Anna Vicco[1], Natsuko Imai-Eaton[1], *Pathogen Epidemiology Review Group*[m], Sabine van Elsland[1], Anne Cori[1], Ruth McCabe[1,^], and Sangeeta Bhatia[1,^]

Affiliations:

[1]MRC Centre for Global Infectious Disease Analysis & WHO Collaborating Centre for Infectious Disease Modelling, Jameel Institute, School of Public Health, Imperial College London, UK

[2]Section for Health Data Science and AI, Department of Public Health, University of Copenhagen, Copenhagen, Denmark

[3]Leverhulme Centre for Demographic Science, Nuffield Department of Population Health, University of Oxford, Oxford, UK

[4]Centre for Artificial Intelligence in Public Health Research, Robert Koch Institute, Berlin, Germany

[*,^] Contributed equally

[m] Membership of group authorship is listed in the Supplementary Information

[#] Corresponding authors: t.naidoo21@imperial.ac.uk, c.morgenstern@imperial.ac.uk

Abstract

We conducted a systematic review (PROSPERO CRD42023393345) characterising the epidemiology, outbreaks and mathematical models of Nipah virus (NiV), an important public health threat in South and Southeast Asia. We extracted 243 parameters, 89 risk factors, 39 models and 23 distinct outbreaks from 119 papers. IgG seroprevalence estimates ranged from 0% to 12.5%. NiV causes severe disease, with pooled case-fatality ratio estimates ranging widely from 9.1% (95%CI: 0.2%-41.3%) in Singapore to 81.9% (95%CI: 71.9%-88.9%) in Bangladesh. NiV's natural history is poorly characterised; we estimated a median incubation period of 8.77 days (95%CI: 7.53-10.02) based on 8 studies. Transmission parameter estimates were scarce, and all but one central estimate of the basic reproduction number were below 1. NiV mathematical models (n=39) were rarely fitted to data (n=8). All extracted information is accessible via our R package, *epireview*, a dynamic resource for informing responses to future outbreaks of NiV and related pathogens.

Keywords: Nipah virus, NiV, systematic review, epidemiological parameters, transmissibility, mathematical model.

Introduction

Infectious diseases pose a continuous threat to global health security, with grave societal and economic consequences, as exemplified by recent public health crises including mpox and COVID-19[1–3]. To guide pandemic preparedness, the World Health Organisation (WHO) has identified pathogens with epidemic and pandemic potential for prioritisation for research and development. Nipah virus (NiV), belonging to the Paramyxoviridae family of viruses, which includes henipaviruses, is one such priority pathogen[4].

NiV was first identified in 1998 in Peninsular Malaysia via an outbreak in commercially-farmed pigs, which then spread nationally through infected pig movements[5] and repeated spillover into humans, and to Singapore through exported pig meat[6,7]. Most human cases resulted from exposure to pigs[8]. The outbreak was contained through livestock movement restrictions and culling of over a million pigs[9]. Between its emergence in 1998 and effective control in 1999, 283 cases of acute encephalitis, a severe symptom of NiV, and 109 deaths were reported in Malaysia, with likely many undetected infections[10–12]. A further 11 cases and one death were reported in Singapore[13] during this period. The outbreak resulted in long-term changes to pig-farming in Malaysia, with pig-rearing banned in some regions or outside of designated "Pig Farming Areas". Malaysia was declared and has remained NiV-free since 2001[14].

The next documented NiV emergence occurred in 2001 in Bangladesh[15] and the neighbouring Indian state, West Bengal[16], both identified retrospectively using serology. Direct spillover from bats to humans and onward human-to-human transmission were documented, suggesting distinct epidemiology and transmission dynamics compared to the first outbreak[8]. Since 2001, Bangladesh has experienced spillover almost annually, becoming the centre of global NiV activity[17]. Since 2018, isolated outbreaks have also been reported in Kerala (India)[18], and confirmed cases were reported in West Bengal in early 2026[19]. The Philippines experienced an outbreak in 2014, with documented spillover from horses to humans and human-to-human transmission [20].

As of February 2026, documented NiV activity in humans is limited to India and Bangladesh. However, the virus is present in bats across South and Southeast Asia[21,22], suggesting a broad geographical area of potential zoonotic spillover risk. This, combined with past evidence of human-to-human transmission and the lack of medical countermeasures, makes NiV a potent threat. A comprehensive understanding of NiV is therefore essential for pandemic preparedness. In particular, epidemiological parameters form crucial inputs for designing outbreak control policies and mathematical models that can be used to inform public health response and rollout strategies should pharmaceutical interventions, e.g. a vaccine, become available[23]. Despite a large body of literature, there is currently no systematic, up-to-date and dynamic collation of NiV epidemiological parameter estimates; current reviews focus only on specific aspects of its epidemiology, such as severity.

As part of a broader effort to collate a comprehensive library of the epidemiology of WHO
priority pathogens, we have previously conducted systematic reviews of outbreaks,
mathematical models, and epidemiological parameter estimates for five other priority
pathogens[24–28]. This study presents a systematic review of published epidemiological
parameter estimates, outbreaks and mathematical models of NiV. We have made the
extracted data available in a user-friendly, open-source R package, *epireview*[29], which can be
easily accessed and updated by the research community.

Methods

87 We followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses
88 (PRISMA) guidelines and registered our study protocol with PROSPERO (International
89 Prospective Register of Systematic Reviews, #CRD42023393345).

Search strategy and selection criteria

We searched PubMed and Web of Science for studies published from database inception up
to 8 March 2019 and repeated the search to include publications through 14 March 2025.
Results were imported into Covidence (2024)[30] and de-duplicated. Titles and abstracts, and
then full texts, were independently screened by two reviewers (selected from TN, CM, TR,
PD, JH, AM, RE, SR, LC, NI-E, RM, SB), and conflicts resolved by consensus. Non-peer-
reviewed literature and non-English language studies were excluded (see appendix p.4, p.58
and Table A.1).

Data extraction

Twelve individuals (TN, CM, TR, PD, RJ, RS, JH, AH, RE, AC, RM, SB) extracted
information from the studies retained after full-text screening. 23.5% (n=28) of all included
papers (n=119) meeting the inclusion criteria were randomly selected and double-extracted to
validate the extraction process. A consensus on discordant results was established, after
which the 12 extractors independently conducted single extraction on the remaining studies.
Data on publication details, transmission model details, historical outbreaks, any
epidemiological delays (e.g. incubation period or symptom-onset-to-hospitalisation or
hospitalisation-to-outcome delays), case fatality ratios (CFRs), basic and effective
reproduction numbers, attack rates, growth rates, overdispersion, seroprevalence, and risk
factors, were extracted using Research Electronic Data Capture (REDCap) hosted at
Imperial[31,32]. Each extractor also undertook a quality assessment (QA) of the paper (using a
customised questionnaire; appendix p.11 and p.16). We extracted statistical uncertainty and
population variability across all parameters (appendix p.14). For risk factors, we only
extracted the outcome (e.g. infection), whether a factor was reported as statistically
significant, and whether the analysis was adjusted for other covariates. We did not extract
quantitative measures of association (e.g. odds ratios) as differences in reference groups and
stratification made comparison across studies challenging.

We excluded systematic reviews from our study but used them to cross-check that all eligible
studies were included (appendix p.58). Full details of the data and extraction process are
provided in the appendix (appendix p.6; Tables A.2-A.4; Tables B.8-B.14).

Data analysis

QA scores for each article were calculated as the proportion of 'Yes' responses to applicable
questions. Temporal trends in QA scores were assessed using local polynomial regression
(appendix Figure B.2).

Historical outbreaks extracted from the literature were deduplicated to account for multiple
articles reporting the same information (appendix p.12, p.20-23).

Extracted CFR parameters were deduplicated ahead of meta-analysis (appendix p.13). We
supplemented our severity analysis with CFR estimates obtained from two complementary
data sources. The first was the deduplicated extracted historical outbreaks, providing more
comprehensive information, particularly on cases in India. The second, specific to
Bangladesh, was surveillance data from the Institute of Epidemiology, Disease Control and
Research (IEDCR), providing a unique opportunity for temporal analyses using a single
surveillance system (appendix p.14 and Table B.8).

For our primary severity analysis, we conducted a meta-analysis of deduplicated CFR using
the *meta* R package[33]. We also conducted a meta-analysis of incubation period estimates.
Common and random effects models were used to generate pooled estimates with 95%
confidence interval (CI) and I^2 heterogeneity estimates (appendix p.13-14). Unless otherwise
stated, we report pooled random-effects estimates. We did not perform meta-analyses for
other parameters because too few central estimates with suitable measures of population
variability were available.

For each of the two complementary severity data sources, we estimated naïve CFRs (number
of reported deaths divided by number of reported cases). For deduplicated outbreaks, we
estimated a pooled CFR using a mixed-effect model, following the same approach used for
the extracted parameter CFR meta-analysis described above. In stratified analyses, some
groups may contain only a single estimate; in such cases, the naïve CFR is reported. Because
IEDCR surveillance data originate from a single source, accounting for between-estimate
heterogeneity was unnecessary, and we instead report naïve CFRs with binomial confidence
intervals.

Analyses were conducted in *R* (version 4.2.2)[34]; curated data on outbreaks, models, and
epidemiological parameters are available from the *epireview* R package[29] (appendix p.59).

Results

The search returned 2,863 potentially relevant articles. De-duplication retained 1,970 articles
for title and abstract screening. Subsequently, 407 studies underwent full-text screening, of
which 119 met the inclusion criteria (appendix, p.5). The main reasons for study exclusion
were "no original estimates" (n=148) and "no reported parameters or models of interest"
(n=76) (Figure 1, see appendix p.5 for Cohen's kappa for the screening and full-text review).

We extracted 243 parameter estimates and 89 risk factors from 119 articles (appendix Tables
B.6-B.7). Furthermore, we extracted 66 outbreaks from 30 articles (appendix p.20-23),
corresponding to 23 distinct outbreaks, totalling 656 cases and 351 deaths, after accounting
for duplicated reporting. We also extracted 39 models from 39 articles (appendix p.24-26).

After deduplication of outbreaks, we identified 14 outbreaks in Bangladesh (range 1-44 cases
per outbreak), six in India (1-66 cases per outbreak), and one each in Malaysia (283 cases),
Singapore (11 cases), and the Philippines (17 cases) (Figure 2A).

We extracted 93 seroprevalence estimates from 43 articles (Figure 2B), reported from seven
countries (Malaysia n=36 estimates; Bangladesh n=22; India n=21; Singapore n=7;
Cambodia n=2; Cameroon n=2; Thailand n=2; Philippines n=1). Only 7 estimates related to
the general population, from studies undertaken in Malaysia (n=4 estimates), Thailand (n=2)
and Bangladesh (n=1) with central estimates of IgG seroprevalence ranging between 0% and
12.5%. Ten estimates were among groups at potentially high risk of exposure: six estimates
came from abattoir workers in Malaysia (n=3) and Singapore (n=3), with central estimates
ranging from 1.4% (IgM)[35] to 57.1% (neutralising antibodies)[6]; while four estimates focussed
on healthcare workers in Malaysia (n=2 estimates) and Bangladesh (n=2), with only 2 of 105
individuals in Bangladesh testing positive for IgG antibodies and all others showing no
evidence of seropositivity. The remaining estimates (n=55) were predominantly related to
persons under investigation and were highly variable (from 0% to 100%) with no clear driver
of heterogeneity, such as location, population group, or assay type. Notably, Pernet et al.[36]
reported a seroprevalence of 3% (n=7 positives of 227 tests using a neutralisation assay)
among individuals exposed to bats in Cameroon, a country which has never reported cases of
NiV. The studies in Thailand and Cambodia found no evidence of seropositivity[37].

We extracted two parameters characterising disease severity: the proportion of cases who are
symptomatic, and CFRs. Estimates of the proportion of symptomatic cases were scarce but
consistently high, with central estimates from three studies[38–40] ranging from 78.3% to 100%
(Figure 3A). CFR estimates were more commonly reported; we extracted 64 estimates from
36 articles (appendix Table B.12), which were reduced to 17 estimates from 15 articles after
deduplication. The deduplicated extracted CFR central estimates were quite variable, ranging
from 9.1% to 100% (Figure 3B), with a pooled estimate of 69.4% (95%CI 53.7%-81.6%, I^2:
85.9%) (Figure 3C). These findings underline both the high lethality of NiV, and high
heterogeneity between estimates.

To explore potential drivers of heterogeneity in extracted CFR estimates, we performed
multiple stratified analyses. There was no obvious variation by population group (Figure 3B,
appendix Figure B.9B), but heterogeneity was evident over time and countries (appendix
Figure B.8, Figure 3C). Stratification by time suggested an increase in CFRs, with pooled
estimates increasing from 37.4% (95%CI: 32.1-43.1%, I^2: 50.5%) in 1998-1999 to 72.5%
(95%CI: 65.9-78.2%, I^2: 10.0%) in 2000-2009 and 85.4% (95%CI: 71.0%-93.3%, I^2: 68.5%)
in 2010-2019. Only one deduplicated estimate was available from 2020 onwards (33.3%,
India) (appendix Figure B.9A). However, these results may also reflect geographic
heterogeneity in CFRs. Early outbreaks in Malaysia (pooled effect CFR estimate: 38.5%,
95%CI 33.0-44.3%, I^2: 34.0%) and Singapore (9.1%, 95%CI: 0.2-41.3%) had significantly
lower estimated CFRs than later outbreaks in Bangladesh (81.9%, 95%CI 71.9-88.9%, I^2:
53.6%) and India (77.8%, 95%CI 47.8-93.1%, I^2: 59.4%). The CFR in the Philippines was
between these two extremes (52.9%, 95%CI 27.8-77.0%).

We further explored geographic heterogeneity in CFR using the estimates from the
deduplicated outbreak data. This pooled CFR (69.8%, 95%CI: 57.8-79.7%, I^2: 73.8%) was
very similar to that obtained from the extracted parameters (Figure 3C), and stratified
analyses confirmed substantial heterogeneity by country (appendix Figure B.6). The IEDCR
data provided an additional opportunity to examine temporal variation in CFR. The naive
CFR over the entire period (2001-2025) was 71.8% (95%CI 66.7%-76.4%), lower than
estimates for this country based on either extracted parameters (Figure 3C) or outbreaks
(appendix Figure B.6). We found no clear temporal trend (appendix Figure B.8). Taken
together, results across all three data sources suggest that country was the most important
driver of CFR heterogeneity.

We identified 69 estimates of epidemiological delay parameters reported in 30 articles
(Figure 4).

We extracted 21 estimates of the incubation period from 16 articles (Figure 4A). Estimates
were broadly consistent across location, time and population group, centring around 8-10
days (n=14 estimates). Nonetheless, some central estimates were as low as 4 days[41], in
persons under investigation in Bangladesh in 2008, and as high as 13 days[42], among
hospitalised patients in Malaysia throughout 1998-1999. Population variability in the
incubation period was wider in the initial Malaysian outbreak (2 days-2 months) than in later
outbreaks in India (4-20 days), Bangladesh (2-14 days), and the Philippines (3-20 days)
across all estimates. The total random effect mean estimate of the median incubation period
was 8.77 days (95%CI: 7.53-10.02, I^2: 86.3%) (Figure 4B).

We found a single estimate of the serial interval in Nikolay et al.[43], with an observed median
of 13 days, an interquartile range of 12 to 14 days, and an estimated mean of 12.7 days and a
standard deviation of 3 days, obtained by fitting a gamma distribution to observed data from
cases in Bangladesh (Figure 4C).

We extracted 35 estimates of delays from symptom onset to various outcomes (Figure 4D-E).
In general, estimates within countries were broadly consistent with notable variability across
countries. The time between onset to admission (n=7 estimates) was very short, with central
estimates ranging from 3.1-4 days in Malaysia (n=5), and consistent at 4 days for both
Bangladesh (n=1) and India (n=1). In Bangladesh, two estimates of the time between onset
and severe illness (appendix p.32-33) were also 4 days, suggesting that admission coincided
with severe symptoms. In contrast, in Malaysia, the time from onset to severe illness was
longer, ranging from 5.8-6.9 days (n=4 estimates), suggesting that typically, patients became
severely ill after admission.
Estimates of onset to death were predominantly from Bangladesh (n=11), with central
estimates ranging from 4-6 days, only marginally longer than the time to admission and
severe illness, and were substantially lower than the corresponding estimates for Malaysia
(n=6 estimates, range 9.5-16 days) and for India (n=1 estimate, central estimate 18.5 days)
(Figure 4E). The time between hospital admission and recovery or death was less well
characterised than the onset-to-outcome delays (Figure 4F). The two admission-to-recovery
estimates were from Malaysia (18.8 days and 34.4 days) and were substantially greater than
the three admission-to-death estimates (2 days in Bangladesh, 2–3.4 days in India).

Transmissibility was poorly characterised overall; all extracted estimates related to
Bangladesh. We extracted five basic reproduction number estimates, with all but one of the
central estimates falling below the critical threshold of 1 (range 0.2-0.88) (Figure 5A)[44–47]. A
central estimate of 1.1 was estimated for a subgroup of patients over 45 years old and
suffering from breathing difficulties; however, the overall estimate from this study was 0.33
(95%CI 0.19-0.59)[43]. We did not find any effective reproduction number estimates in the
literature. Only one article, by Hsu et al[15], reported attack rates, namely 1.1% for the
Naogaon outbreak and 2.1% for the Meherpur outbreak (Figure 5B). Overdispersion,
measured as the maximum number of secondary cases caused by an infector, was reported as
21 and 22 in two articles[38,43] (Figure 5C), although we were unable to verify if this referred to
the same individual.

Nucleotide substitution rates were reported in five articles[48–52], with substantial variation in
central estimates, ranging from 2.18×10^{-4} to 11.0×10^{-4} substitutions per site year (s/s/y)
(Figure 5D). We note that the highest estimate, from Li et al. [50], is almost twice the next
largest estimate of Lo Presti et al.[48], has wide uncertainty (95% highest posterior density
interval of 7.37×10^{-4} to 15.0×10^{-4} s/s/y), and an extremely wide range of disaggregated
central estimates (11.0×10^{-4} to 143.0×10^{-4} s/s/y).

Risk factors were recorded for six outcomes, with information predominantly coming from
Bangladesh and Malaysia: spillover risk (Bangladesh (n=17) and Thailand (n=1)), infection (
Bangladesh (n=30) and Malaysia (n=6)), seropositivity (Malaysia (n=5) and Bangladesh,
Cameroon and Singapore (n=2 each)), death (Malaysia (n=6) and Bangladesh (n=3)),
neurological symptoms (n=1 from Malaysia), and other (Bangladesh (n=6), Malaysia (n=7)
and India (n=1); for example, isolation of the virus from samples or risk of specific clinical
manifestations including seizures) (Table B.14 and B.16).

Contact with animals was considered as a risk factor for spillover in only one study in
Bangladesh, which found a significant association[53]. Environmental variables such as rainfall
or temperature were frequently considered as potential risk factors for spillover (n=4; n=5;
n=10 estimates, respectively), but articles reported both significant and non-significant
associations.

Close contact was often found as a significant risk factor for infection (n=11 articles reporting
it as significant versus n=4 reporting it as not significant, all from Bangladesh). Contact with
animals was more often found not significant (n=12) than significant (n=6) for infection as
reported from studies in Bangladesh and Malaysia. Sex (n=10 parameters), occupation (n=9),
age (n=5), and environmental factors (n=3) were reasonably balanced in terms of being
reported as significant or not significant for infection.

Sex and close contact were found as significant risk factors for seropositivity across all
studies, whereas the environment was a significant factor in the study from Cameroon. Age
and contact with animals were reported as risk factors for serology, with articles noting both
significant (age: n=2 from Bangladesh and Malaysia; contact with animals: n=3 from
Bangladesh, Cameroon and Singapore) and non-significant associations (age: n=3; contact
with animals: n=4, both from Malaysia and Singapore).

Although age was significantly associated with death from NiV (n=4 from Bangladesh and
Malaysia), contact with animals (n=1 from Malaysia) and sex (n=1 from Bangladesh) were
not significant[54,55]. Full details of the remaining risk factors are provided in the appendix
Table B.14.

Mathematical models for NiV transmission began to be published from 2020 onwards (Figure
B.4 and Table B.9). All 39 extracted models were compartmental models, except one, which
used a branching process[56]; 35 were deterministic, while the remaining four were stochastic.
20 models included zoonotic spillover, and three had spatial structure. However, only eight
models were fitted to data, and only six models considered uncertainty (e.g. through multiple
stochastic runs or sensitivity analyses). 13 papers specified the coding language used, with
six articles using Python, five using MATLAB, and two using R. Only three articles
published their code alongside the articles.

Our temporal analysis of QA scores (excluding mathematical modelling studies) showed that
the mean QA score assigned by extractors steadily increased since 1999 (appendix p.16).
Overall, the data extractors tended to assign lower quality scores to modelling studies,
possibly because many of these studies used transmission models that were not fitted directly
to data (appendix p.24-26).

We assessed the risk of publication bias associated with the meta-analyses presented here to
be low (appendix Figures B.10, B.17) since we conducted meta-analyses on observed disease
parameters (severity and the median incubation period), which are themselves less likely to
be subject to selective reporting of positive results.

Discussion

In this systematic review, we have collated and analysed epidemiological parameters,
outbreaks and mathematical models of NiV to provide a comprehensive overview of NiV
epidemiology.

After the initial outbreaks of NiV in Malaysia and Singapore in 1998, reported cases in
humans have been confined to South and Southeast Asia, with recurrent outbreaks in
Bangladesh (since 2001) and Kerala, India (since 2018) and sporadic outbreaks in West
Bengal[57], India (since 2001), and a single documented outbreak in the Philippines (2014)[58,59].
The outbreaks in South Asia have been notably smaller than in the initial Malaysian outbreak,
often reporting less than 30 cases, with some notable exceptions, for example, the 2001
outbreak in West Bengal which recorded 66 cases[9,60].

Despite the temporal proximity of the 1998-1999 outbreak in Malaysia and the 2001 outbreak
in Bangladesh, extensive evidence, including genomic investigations[61], suggests that these
two outbreaks were unlinked, distinct events, caused by distinct NiV strains, NiV Malaysia
(NiV-M)[62] and NiV Bangladesh (NiV-B)[16,61]. These differences are reflected in parameter
estimates, particularly transmissibility, epidemiological delays and severity, for which we
found substantial spatiotemporal heterogeneity. However, it is challenging to disentangle the
potential contributions of time, transmission route, strain-specific characteristics and local

factors (e.g. related to disease surveillance, health care systems or environmental conditions)
as drivers of the observed heterogeneity[28,63,64].

The transmissibility of NiV (reproduction numbers, attack rates, and overdispersion) was
generally poorly characterised in the literature. The limited parameter estimates were all from
Bangladesh, despite Malaysia reporting the largest documented NiV outbreak to date[9]. The
estimates of the basic reproduction number, nearly all below the critical threshold of one,
suggest a lack of sustained human-to-human transmission. However, when there was human-
to-human transmission, extracted overdispersion estimates suggest high potential for
superspreading, presenting a challenge for outbreak control[65,66].

Seroprevalence studies can shed further light on the transmissibility of NiV, with the low
estimates in general populations supporting a lack of widespread transmission, potentially
due to a variety of factors including localised risk of spillover, limited onward transmission
chains, or the time elapsed since exposure. However, only seven of 93 seroprevalence
estimates were undertaken in the general population, and did not cover all areas with reported
cases, namely India, Singapore or the Philippines. Of the limited evidence among high-risk
groups, seropositivity appears to be higher among abattoir workers than in healthcare
workers, but further studies are required before any strong conclusions can be drawn
regarding this risk.

The 89 extracted risk factors were predominantly evaluated for Bangladesh, with infection
and spillover risk the outcomes most frequently considered. There was a lack of conclusive
evidence: many risk factors, including sex and environmental factors, presented as significant
an equal number of times as they presented as non-significant. Age was consistently
associated with mortality; close contact with infected individuals was unsurprisingly found to
be a driver of infection across multiple studies. Throughout, contact with animals was often
not found to have a significant association with infection or serology, despite the documented
role of zoonotic spillover of NiV. This may be attributable to study design, including
definitions of animal contact that are too broad or unspecific[67].

We found paucity of data on the natural history of NiV, with only one estimate of the serial
interval, and a small number of estimates for the time between key milestones, including
symptom onset, hospital admission and recovery. The only exceptions were the incubation
period (21 estimates) and time between symptom onset and death (18 estimates). Parameters
estimates were generally consistent within country and exhibited substantial heterogeneity
across countries. In Malaysia, severe illness generally occurred after hospitalisation, whereas
in Bangladesh, the evidence suggests that these two events coincided. This may imply that
hospitalisation in Bangladesh is potentially triggered by severe symptoms, but it could also
signify different clinical courses of NiV in these locations.

Our results underline the high severity of NiV. Available estimates of the proportion of
symptomatic cases, while sparse, suggest that more than three-quarters of infections are
symptomatic[38–40]. Furthermore, the disease progression tends to be rapid (4-7 days from onset
to severe disease) often culminating in a fatal outcome. Our overall meta-analysis of CFR
estimates yielded a high pooled estimate of 69.4% (95%CI 53.7-81.6%). Since multiple
studies can report CFR that rely on the same data, we deduplicated the published estimates to

ensure a robust and unbiased meta-analysis. While most published estimates of the overall
CFR were consistent with our estimate, our deduplication of estimates likely explains any
differences[68–70].

Consistent with other parameters, we found that geography was the primary driver of
heterogeneity across CFR estimates, with lower estimates for the outbreaks in Malaysia and
Singapore (38.5% and 9.1%, respectively) than for outbreaks in India and Bangladesh (77.8%
and 81.9%, respectively). The CFR for the outbreak in the Philippines (52.9%) was between
these two extremes, although this must be considered in the context of an isolated outbreak
with a distinct spillover mechanism. Temporal trends in CFR could serve as an alternative
explanation for these differences, with initial outbreaks having a lower CFR. To investigate
these alternative hypotheses, we also analysed IECDR data[71], which covers each year since
2002. This analysis did not show a significant temporal association with the CFR (appendix
p.49). While preliminary, these results suggest that geographic differences are a plausible
explanation for the observed heterogeneity. Disentangling the drivers of these differences
across geographies is challenging, as observed severity can reflect a combination of intrinsic
virulence, potentially influenced by viral lineage, and contextual factors including disease
surveillance, diagnostic capacity, access to healthcare, and therapeutic options, all of which
warrant further investigation[72–74].

The heterogeneity across countries in key parameters is reflected in the distinct dynamics and
the host species. Three different species have played a key role in spillover across different
groups of outbreaks: pigs in Malaysia and Singapore, horses in the Philippines and bats in
Bangladesh and India, all of which are present globally. Serosurveys conducted in animals
indicate the presence of anti-Nipah antibodies in *Pteropus medius* bats in Indian states that
have so far not reported any Nipah activity in humans[75,76]. Similar findings from other
regions in the world[77] outside the "Nipah belt" suggest a wider geographical zone with
potential spillover risk mediated by seasonal dynamics, viral shedding in bats, bat behaviour,
and local human practices such as the consumption of contaminated fruits. For example, the
2014 study by Pernet et al. found NiV cross-neutralising antibodies in 3-4% of 227 bat-
exposed individuals in Cameroon, a region where no NiV activity in humans has yet been
reported[78]. The symptoms of NiV disease are clinically similar to other pathogens that cause
febrile illness and so it is plausible that, as with the Malaysian outbreak, spillover incidents
are misdiagnosed or undetected[58]. The fact that NiV is characterised by recurring spillover
events from infected hosts underlines it as a canonical example of the need for a One Health
approach to surveillance.

Mathematical modelling is increasingly being used to answer key policy questions that arise
during public health crises, ranging from an assessment of severity to that of the efficacy of
interventions, or designing clinical trials[79,80]. Our review identified only 39 mathematical
modelling studies of NiV, all of which were published since 2020 despite most reported cases
and outbreaks occurring far before this period. Only eight (of 39) studies were fitted to data
and only three had available code. It is noteworthy that all models in the review were
published since 2020, similar to findings from our related reviews on other pathogens[25,26],
with one hypothesis being that the attention modelling received during the COVID-19

pandemic inspired a surge in its use across other pathogens. However, the studies with
mathematical models in our review generally had low QA scores indicating an important
knowledge gap deserving of further research; we consider that this review provides a strong
foundation upon which to begin addressing this.

Our study has some limitations. First, we excluded literature that was not in English or not
peer reviewed. This includes information on most of the outbreaks that have occurred in
India[81,82], which are only documented in the grey literature. However, we do not expect to
have missed many parameter estimates or models, which are predominantly published in
peer-reviewed journals. Second, this review focused on human hosts and excluded studies
focused on animal hosts only, to limit the scope of our research. Third, we did not extract all
disaggregated data from studies on factors such as age, region, or time due to limited
resources; we have noted in the associated *epireview* database all instances where
disaggregated data is available so that researchers can access and/or extract it in the future.
Fourth, we extracted risk factors without quantitative estimates because the underlying
methods and group definitions varied widely. Information on risk factor studies are annotated
in *epireview* to make them easier to find. Fifth, despite our best efforts to achieve
concordance among data extractors, some discrepancies may remain. We have extensively
documented our data extraction guidelines for transparency.

In this study, we have provided a comprehensive overview of past outbreaks, key
epidemiological parameters, and mathematical models for NiV. Our work confirms that NiV
is a concerning pathogen with potential for causing outbreaks with high severity. We have
also highlighted critical knowledge gaps - we note that a large body of evidence is drawn
from the outbreaks in Bangladesh. Taken together with the observed spatial variation in NiV
epidemiology, it suggests a blind spot in our understanding of this virulent virus. The data
extracted in this study, and in our previous works for Marburg, Ebola, Lassa, SARS, and Zika
are available to the wider community via our open-source R package *epireview* to inform
future research and public health responses. *epireview* enables easy updating of our data
library, turning the current collation into a living and evolving resource for the public health
research community, which we hope will be expanded upon as the community continues to
monitor and research this highly lethal pathogen.

440
441

Declarations

Funding

All authors acknowledge funding from the Medical Research Council (MRC) Centre for Global Infectious Disease Analysis (MR/X020258/1) funded by the UK MRC and carried out in the frame of the Global Health EDCTP3 Joint Undertaking supported by the EU; the National Institute for Health Research (NIHR) Health Protection Research Unit in Health Analytics & Modelling (NIHR207404), a partnership between UK Health Security Agency (UKHSA), London School of Hygiene & Tropical Medicine, and Imperial College of Science, Technology, & Medicine. The views expressed are those of the author(s) and not necessarily those of the NIHR, UKHSA, or the Department of Health and Social Care. CM acknowledges Schmidt Sciences for research funding (grant code 6–22–63345). PD, TN, and RJ acknowledge funding from Community Jameel. RJ acknowledges funding from CEPI. KM acknowledges research funding from the Imperial College President's PhD Scholarship. TR was supported by the Moh Family Foundation and the Leverhulme Trust (Grant RC-2018-003) for the Leverhulme Centre for Demographic Science. AV acknowledges funding from Wellcome Trust (226072/Z/22/Z). AMH acknowledges funding from the German Federal Ministry of Research, Technology and Space (BMFTR) through the CLIMADEMIC project (funding code 01LN2210A) within the framework of the Strategy Research for Sustainability (FONA). The funders of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. For the purpose of open access, the author has applied a 'Creative Commons Attribution' (CC BY) licence to any Author Accepted Manuscript version arising from this submission.

Availability of data and materials https://github.com/mrc-ide/epireview/tree/main/data

Code availability https://github.com/mrc-ide/epireview; https://github.com/mrc-ide/priority-pathogens

PROSPERO CRD42023393345
(https://www.crd.york.ac.uk/prospero/display_record.php?RecordID&RecordID=393345)

Competing interests AC reports payment from Munich Re for consulting on modelling the likelihood and severity of pandemics. PD reports payment from WHO for consulting on integrated modelling. RM has received payment from WHO for work on MERS-CoV. HJTU reports payment from the Moderna Charitable Foundation (paid directly to the institution for an unrelated project). All other authors declare no competing interests. The views expressed are those of the authors and not necessarily those of the National Institute for Health and Care Research (NIHR), UK Health Security Agency, or the Department of Health and Social Care. NI-E is currently employed by Wellcome. However, Wellcome had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. AMH received additional funding from Gavi, Bill & Melinda Gates Foundation and the Wellcome Trust via the Vaccine Impact Modelling Consortium (VIMC) during the course of the study (grant number INV-034281). These funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Authors' contributions

SB, SE, AC, and NI conceptualised this systematic review. TN, CM, TR, SR, LC, and SB searched the literature and screened the titles and abstracts. TN, CM, TR, PD, RJ, RS, JH, AH, RE, AC, RM, and SB reviewed all full-text articles. TN, CM, TR, PD, RJ, RS, JH, AMH, RE, AC, RM, and SB extracted the data. TN, CM, RM, and SB formally analysed, visualised, and validated the data. TN, CM, and SB were responsible for the software infrastructure. AC acquired funding. CM, SB, RM, and AC were responsible for project administration. TR and SE were responsible for training individuals to use Covidence and for designing the REDCap form. CM, RM, and SB supervised the systematic review. TN, CM, RM, and SB wrote the original manuscript draft. All authors were responsible for the methodology, review, and editing of the manuscript. All authors debated, discussed, edited, and approved the final version of the manuscript. All authors had final responsibility for the decision to submit the manuscript for publication.

References

Laurenson-Schafer H, Sklenovská N, Hoxha A, *et al.* Description of the first global outbreak of mpox: an analysis of global surveillance data. *Lancet Glob Health* 2023; **11**: e1012–23.

Sokunbi TO, Akinbi EO. The cost of the reemergence of monkeypox: An overview of health financing in Africa. *Health Policy OPEN* 2024; **7**: 100132.

Faramarzi A, Norouzi S, Dehdarirad H, Aghlmand S, Yusefzadeh H, Javan-Noughabi J. The global economic burden of COVID-19 disease: a comprehensive systematic review and meta-analysis. *Syst Rev* 2024; **13**: 68.

World Health Organization. Prioritizing Diseases for Research and Development in Emergency Contexts. 2026. https://www.who.int/activities/prioritizing-diseases-for-research-and-development-in-emergency-contexts.

Chua KB, Goh KJ, Wong KT, *et al.* Fatal encephalitis due to Nipah virus among pig-farmers in Malaysia. *The Lancet* 1999; **354**: 1257–9.

Chan KP, Rollin PE, Ksiazek TG, *et al.* A survey of Nipah virus infection among various risk groups in Singapore. *Epidemiol Infect* 2002; **128**: 93–8.

Paton NI, Leo YS, Zaki SR, *et al.* Outbreak of Nipah-virus infection among abattoir workers in Singapore. *The Lancet* 1999; **354**: 1253–6.

Ang BSP, Lim TCC, Wang L. Nipah Virus Infection. *J Clin Microbiol* 2018; **56**: e01875-17.

Chua KB, Bellini WJ, Rota PA, *et al.* Nipah Virus: A Recently Emergent Deadly Paramyxovirus. *Science* 2000; **288**: 1432–5.

Wong KT, Shieh WJ, Zaki SR, Tan CT. Nipah virus infection, an emerging paramyxoviral zoonosis. *Springer Semin Immunopathol* 2002; **24**: 215–28.

Looi LM, Chua KB. Lessons from the Nipah virus outbreak in Malaysia. *Malays J Pathol* 2007; **29**: 63–7.

Chua KB. Nipah virus outbreak in Malaysia. *J Clin Virol* 2003; **26**: 265–75.

US CDC. Outbreak of Hendra-like virus–Malaysia and Singapore, 1998-1999. *MMWR Morb Mortal Wkly Rep* 1999; **48**: 265–9.

World Organisation for Animal Health. Self-declaration: Malaysia — Nipah virus. World Organisation for Animal Health (WOAH), 2001 https://www.woah.org/fileadmin/Home/eng/Animal_Health_in_the_World/docs/pdf/Self-declarations/Archives/Pages_de_Bull_2001-4-ENG_MYS_NPH.pdf.

Hsu VP, Hossain MJ, Parashar UD, *et al.* Nipah Virus Encephalitis Reemergence, Bangladesh. *Emerg Infect Dis* 2004; **10**: 2082–7.

16 Chadha MS, Comer JA, Lowe L, *et al.* Nipah Virus-associated Encephalitis Outbreak,
Siliguri, India. *Emerg Infect Dis* 2006; **12**: 235–40.

17 Satter SM, Aquib WR, Sultana S, *et al.* Tackling a global epidemic threat: Nipah
surveillance in Bangladesh, 2006–2021. *PLoS Negl Trop Dis* 2023; **17**: e0011617.

18 Arunkumar G, Chandni R, Mourya DT, *et al.* Outbreak Investigation of Nipah Virus
Disease in Kerala, India, 2018. *J Infect Dis* 2019; **219**: 1867–78.

19 UK Health Security Agency. Outbreaks under monitoring: week 3 (week ending 18
January 2026). 2026. https://www.gov.uk/government/publications/outbreaks-under-
monitoring-in-2026/outbreaks-under-monitoring-week-3-week-ending-18-january-2026.

20 Ching PKG, De Los Reyes VC, Sucaldito MN, *et al.* Outbreak of Henipavirus
Infection, Philippines, 2014. *Emerg Infect Dis* 2015; **21**: 328–31.

21 Breed AC, Meers J, Sendow I, *et al.* The Distribution of Henipaviruses in Southeast
Asia and Australasia: Is Wallace's Line a Barrier to Nipah Virus? *PLoS ONE* 2013; **8**:
e61316.

22 Li Y, Wang J, Hickey AC, *et al.* Antibodies to Nipah or Nipah-like Viruses in Bats,
China. *Emerg Infect Dis* 2008; **14**: 1974–6.

23 Coalition for Epidemic Preparedness Innovations (CEPI). New vaccine set for human
trials in Nipah outbreak hotspot. 2025; published online July 10. https://cepi.net/new-
vaccine-set-human-trials-nipah-outbreak-hotspot.

24 Cuomo-Dannenburg G, McCain K, McCabe R, *et al.* Marburg virus disease
outbreaks, mathematical models, and disease parameters: a systematic review. *Lancet Infect*
Dis 2024; **24**: e307–17.

25 Nash RK, Bhatia S, Morgenstern C, *et al.* Ebola virus disease mathematical models
and epidemiological parameters: a systematic review. *Lancet Infect Dis* 2024; **24**: e762–73.

26 Doohan P, Jorgensen D, Naidoo TM, *et al.* Lassa fever outbreaks, mathematical
models, and disease parameters: a systematic review and meta-analysis. *Lancet Glob Health*
2024; **12**: e1962–72.

27 Morgenstern C, Rawson T, Routledge I, *et al.* Severe acute respiratory syndrome
(SARS) mathematical models and disease parameters: a systematic review. *Lancet Microbe*
2025; : 101144.

28 McCain K, Vicco A, Morgenstern C, *et al.* A systematic review and meta-analysis of
Zika virus epidemiology. *Nat Health* 2026; published online Feb 13. DOI:10.1038/s44360-
025-00051-4.

29 Nash R, Morgenstern C, Santoni C, *et al.* epireview: Tools to update and summarise
the latest pathogen data from the Pathogen Epidemiology Review Group (PERG). 2024
https://mrc-ide.github.io/epireview/.

30 Veritas Health Innovation. Covidence systematic review software. 2024.
www.covidence.org.

31 Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic
data capture (REDCap)—A metadata-driven methodology and workflow process for
providing translational research informatics support. *J Biomed Inform* 2009; **42**: 377–81.

32 Harris PA, Taylor R, Minor BL, *et al.* The REDCap consortium: Building an
international community of software platform partners. *J Biomed Inform* 2019; **95**: 103208.

33 Balduzzi S, Rücker G, Schwarzer G. How to perform a meta-analysis with R: a
practical tutorial. *Evid Based Ment Health* 2019; : 153–60.

34 R Core Team. R: A Language and Environment for Statistical Computing. Vienna,
Austria: R Foundation for Statistical Computing, 2020 https://www.R-project.org/.

35 Sahani M, Parashar UD, Ali R, *et al.* Nipah virus infection among abattoir workers in
Malaysia, 1998–1999. *Int J Epidemiol* 2001; **30**: 1017–20.

36 Pernet O, Schneider BS, Beaty SM, *et al.* Evidence for henipavirus spillover into
human populations in Africa. *Nat Commun* 2014; **5**: 5342.

37 As AK, Sahay RR, Radhakrishnan C, *et al.* Clinico☐epidemiological presentations
and management of Nipah virus infection during the outbreak in Kozhikode district, Kerala
state, India 2023. *J Med Virol* 2024; **96**: e29559.

38 Gurley ES, Montgomery JM, Hossain MJ, *et al.* Person-to-Person Transmission of
Nipah Virus in a Bangladeshi Community. *Emerg Infect Dis* 2007; **13**: 1031–7.

39 Ong HM, Ibrahim PAS, Chong CN, *et al.* Malaysia outbreak survivors retain
detectable Nipah antibodies and memory B cells after 25 years. *J Infect* 2025; **90**: 106398.

40 Kumar CPG, Sugunan AP, Yadav P, *et al.* Infections among Contacts of Patients with
Nipah Virus, India. *Emerg Infect Dis* 2019; **25**: 1007–10.

41 Rahman MA, Hossain MJ, Sultana S, *et al.* Date Palm Sap Linked to Nipah Virus
Outbreak in Bangladesh, 2008. *Vector-Borne Zoonotic Dis* 2012; **12**: 65–72.

42 Sim, Bee-Fung, Chang, Choong-Chor, Khalid, Raihanah. Nipah encephalitis: A report
of 18 patients from Kuala Lumpur Hospital. *Neurol J Southeast Asia* 2002; : 13–8.

43 Nikolay B, Salje H, Hossain MJ, *et al.* Transmission of Nipah Virus — 14 Years of
Investigations in Bangladesh. *N Engl J Med* 2019; **380**: 1804–14.

44 Nikolay B, Salje H, Khan AKMD, *et al.* A Framework to Monitor Changes in
Transmission and Epidemiology of Emerging Pathogens: Lessons From Nipah Virus. *J*
Infect Dis 2020; **221**: S363–9.

45 Sikder AK, Hossain MB, Islam MH. Compartmental modelling in epidemic diseases:
a comparison between SIR model with constant and time-dependent parameters. *Inverse*
Probl 2023; **39**: 035005.

46 Luby SP, Gurley ES, Hossain MJ. Transmission of Human Infection with Nipah
Virus. *Clin Infect Dis* 2009; **49**: 1743–8.

47   Naser AM, Hossain MJ, Sazzad HMS, *et al.* Integrated cluster- and case-based
surveillance for detecting stage III zoonotic pathogens: an example of Nipah virus
surveillance in Bangladesh. *Epidemiol Infect* 2015; **143**: 1922–30.

48   Lo Presti A, Cella E, Giovanetti M, *et al.* Origin and evolution of Nipah virus. *J Med*
Virol 2016; **88**: 380–8.

49   Rahman MZ, Islam MM, Hossain ME, *et al.* Genetic diversity of Nipah virus in
Bangladesh. *Int J Infect Dis* 2021; **102**: 144–51.

50   Li K, Yan S, Wang N, *et al.* Emergence and adaptive evolution of Nipah virus.
Transbound Emerg Dis 2020; **67**: 121–32.

51   Cortes-Azuero O, Lefrancq N, Nikolay B, *et al.* The Genetic Diversity of Nipah Virus
Across Spatial Scales. *J Infect Dis* 2024; **230**: e1235–44.

52   Whitmer SLM, Lo MK, Sazzad HMS, *et al.* Inference of Nipah virus evolution,
1999–2015. *Virus Evol* 2021; **7**: veaa062.

53   Walsh MG. Mapping the risk of Nipah virus spillover into human populations in
South and Southeast Asia. *Trans R Soc Trop Med Hyg* 2015; **109**: 563–71.

54   Hossain MJ, Gurley ES, Montgomery JM, *et al.* Clinical presentation of nipah virus
infection in Bangladesh. *Clin Infect Dis* 2008; **46**: 977–84.

55   Chong HT, Tan C, Goh K, Tan K, others. Occupational exposure, age, diabetes
mellitus and outcome of acute Nipah encephalitis. *Neurol J Southeast Asia* 2001; **6**.

56   Bradbury NV, Hart WS, Lovell-Read FA, Polonsky JA, Thompson RN. Exact
calculation of end-of-outbreak probabilities using contact tracing data. *J R Soc Interface*
2023; **20**: 20230374.

57   World Health Organization. Nipah Virus Infection — Disease Outbreak News (DON
2025-DON577). 2025; published online Aug. https://www.who.int/emergencies/disease-
outbreak-news/item/2025-DON577.

58   World Health Organization. Nipah Virus Infection. 2024. https://www.who.int/health-
topics/nipah-virus-infection#tab=tab_1.

59   Khan S, Akbar SMF, Mahtab MA, *et al.* Twenty-five years of Nipah outbreaks in
Southeast Asia: A persistent threat to global health. *IJID Reg* 2024; **13**: 100434.

60   Harit AK, Ichhpujani RL, Gupta S, *et al.* Nipah/Hendra virus outbreak in Siliguri,
West Bengal, India in 2001. *Indian J Med Res* 2006; **123**: 553–60.

61   Harcourt BH, Lowe L, Tamin A, *et al.* Genetic Characterization of Nipah Virus,
Bangladesh, 2004. *Emerg Infect Dis* 2005; **11**: 1594–7.

62   Harcourt BH, Tamin A, Ksiazek TG, *et al.* Molecular Characterization of Nipah
Virus, a Newly Emergent Paramyxovirus. *Virology* 2000; **271**: 334–49.

63   Shen Y, Liu Y, Krafft T, Wang Q. Progress and challenges in infectious disease

surveillance and early warning. *Med Plus* 2025; **2**: 100071.

64   Cauchemez S, Nouvellet P, Cori A, *et al.* Unraveling the drivers of MERS-CoV
transmission. *Proc Natl Acad Sci* 2016; **113**: 9081–6.

65   Lloyd-Smith JO, Schreiber SJ, Kopp PE, Getz WM. Superspreading and the effect of
individual variation on disease emergence. *Nature* 2005; **438**: 355–9.

66   Fraser C, Riley S, Anderson RM, Ferguson NM. Factors that make an infectious
disease outbreak controllable. *Proc Natl Acad Sci* 2004; **101**: 6146–51.

67   Klous G, Huss A, Heederik DJJ, Coutinho RA. Human–livestock contacts and their
relationship to transmission of zoonotic pathogens, a systematic review of literature. *One*
Health 2016; **2**: 65–76.

68   Suman N, Khandelwal E, Chiluvuri P, *et al.* NIPAH Virus Encephalitis: Unveiling the
Epidemiology, Risk Factors, and Clinical Outcomes – A Systematic Review and Meta-
Analysis. *J Pharm Bioallied Sci* 2024; **16**: S102–5.

69   Khan SA, Imtiaz MA, Islam MM, Tanzin AZ, Islam A, Hassan MM. Major
bat‐borne zoonotic viral epidemics in Asia and Africa: A systematic review and
meta‐analysis. *Vet Med Sci* 2022; **8**: 1787–801.

70   Kenmoe S, Demanou M, Bigna JJ, *et al.* Case fatality rate and risk factors for Nipah
virus encephalitis: A systematic review and meta-analysis. *J Clin Virol* 2019; **117**: 19–26.

71   Institute of Epidemiology, Disease Control and Research (IEDCR). NIPAH Situation
Dashboard. 2026. http://iedcr.portal.gov.bd/pages/static-pages/6922df4d933eb65569e211f1.

72   Jensen PM, De Fine Licht HH. Predicting global variation in infectious disease
severity: A bottom-up approach. *Evol Med Public Health* 2016; **2016**: 85–94.

73   Perez-Guzman PN, Knock E, Imai N, *et al.* Epidemiological drivers of
transmissibility and severity of SARS-CoV-2 in England. *Nat Commun* 2023; **14**: 4279.

74   Satter SM, Sultana S, Choudhury SS, *et al.* Insights into the acute phase of Nipah
virus infection: Clinical features, viral detection, and humoral immune response. *Int J Infect*
Dis 2026; **163**: 108263.

75   Gokhale M. D, Sreelekshmy M, Sudeep AB, *et al.* Detection of possible Nipah virus
infection in Rousettus leschenaultii and Pipistrellus Pipistrellus bats in Maharashtra, India. *J*
Infect Public Health 2021; **14**: 1010–2.

76   Mourya DT, Yadav P, Sudeep AB, *et al.* Spatial Association Between a Nipah Virus
Outbreak in India and Nipah Virus Infection in Pteropus Bats. *Clin Infect Dis* 2019; **69**:
378–9.

77   Cappelle J, Hoem T, Hul V, *et al.* Nipah virus circulation at human–bat interfaces,
Cambodia. *Bull World Health Organ* 2020; **98**: 539–47.

78   Pernet O, Schneider BS, Beaty SM, *et al.* Evidence for henipavirus spillover into
human populations in Africa. *Nat Commun* 2014; **5**: 5342.

79   Bhatia S, Imai N, Watson OJ, *et al.* Lessons from COVID-19 for rescalable data
683   collection. *Lancet Infect Dis* 2023; **23**: e383–8.

684   80   Thomas R. Preparing for Disease X: How maths can help us be ready for the next
685   pandemic. 2024; published online Nov 11. https://plus.maths.org/content/preparing-disease-
686   x.

687   81   World Health Organization. Nipah Virus Disease – India. 2021; published online
688   Sept.   https://www.who.int/emergencies/disease-outbreak-news/item/nipah-virus-disease---
689   india.

690   82   World Health Organization. Nipah Virus – India. 2018; published online Aug 7.
691   https://www.who.int/emergencies/disease-outbreak-news/item/07-august-2018-nipah-virus-
692   india-en.

694
695 *Figure 1: Study selection according to PRISMA guidelines and criteria described in SM-Table B.1. (Reasons for abstract exclusion not recorded in Covidence).*

Figure 2: Overview of extracted outbreaks and seroprevalence estimates. (A) Map of total cases reported in West Bengal and Bangladesh (top left), Kerala (top right), Peninsular Malaysia and Singapore (bottom left), and the Philippines (bottom right). Lines in the outbreak map are coloured as follows, with country boundaries shown in black; state boundaries in brown for all countries in which outbreaks occurred, regardless of whether an outbreak occurred in that specific state; and district boundaries in grey where specified for an outbreak. (B) Forest plot of seroprevalence estimates stratified by short-term antibodies (left) and long-term antibodies (right), and by population type (panels); colours represent countries; parameters with a QA score ≤ 50% are displayed with a lighter shade; inverted triangles, pentagons, stars, and triangles represent IgM, IgG, PRNT, and unspecified assay estimates respectively; black error bars indicate estimate uncertainty, and thick coloured bands indicate ranges across central estimates of disaggregated parameters (e.g. age, sex, time).

705 *Figure 3. Overview of severity estimates. (A) Forest plot of extracted proportion of symptomatic cases. (B) Forest plot of deduplicated extracted CFR estimates stratified by population group.*
706 *(C) Meta-analysis of deduplicated extracted CFR estimates by country. In panels (A) and (B), colours represent countries; parameters with a QA score ≤ 50% have a lighter shade; circles and*
707 *triangles represent mean and unspecified estimate types respectively; and coloured bands indicate ranges across central estimates of disaggregated parameters (e.g. age, sex, time). In panel*
708 *(C), squares represent individual CFR estimates, with black horizontal lines indicating 95%CIs; diamonds represent pooled estimates from common-effect and random-effects models, with*
709 *widths corresponding to 95%CIs. Appendix B, Section 4.1 (p.48-56) presents additional severity results.*

*Figure 4: Overview of extracted epidemiolocal delays and a meta-analysis of incubation periods. (A) Forest plot of incubation periods. (B) Meta-analysis of incubation periods; only delays reported as median (interquartile range), median (range), and mean (standard deviation) are included (appendix p.14). (C) Forest plot of serial intervals. (D) Forest plot of symptom-onset to different outcomes. (E) Forest plot of symptom-onset to death. (F) Forest plot of hospitalisation to outcome. In panels (A, C-E), colours represent countries; parameters from studies with a QA score ≤ 50% are displayed with a lighter shade; circles, squares, and triangles represent mean, median, and unspecified estimate types respectively; solid and dashed black error bars indicate estimate uncertainty and population variability respectively; and thick coloured bands indicate ranges of central estimates of disaggregated parameters across different groups (e.g. age, sex, time). *indicates estimated parameters while all other parameters are observed sample statistics. In panel (D), the discharge/recovery delay range of central estimates reported by Ramasundrum (2000) extends to 83 days. In panel (B), squares represent incubation period estimates from individual studies, with black horizontal lines indicating 95%CIs; diamonds represent pooled estimates from common-effect and random-effects models, with widths corresponding to 95%CIs. Estimates from four studies that reported only population variability without central estimates, as well as a single estimate for symptom onset to death/recovery (combined), were excluded from the figure for readability.*

721
Figure 5: Overview of transmission and genetic parameters. (A) Forest plot of basic reproduction number. (B) Forest plot of attack rates. (C) Forest plot of overdispersion, where the x-axis
represents the maximum number of secondary cases caused by an infector. (D) Forest plot of the nucleotide substitution rates, reported in substitutions per site per year (s/s/y). Panels (A-C) are
stratified by population type. Parameters with a QA score ≤ 50% are displayed with a lighter shade; circles and triangles represent mean and unspecified estimates respectively; and black
*error bars indicate estimate uncertainty, and thick coloured bands indicate ranges across central estimates of disaggregated parameters (e.g. age, sex, time). *Lo Presti (2016) reported this*
metric as an evolutionary rate; a term often used interchangeably with substitution rate in viral phylogenetic analyses. The range of substitution rate central estimates reported by Li (2020)
extends to 143×10^{-4} s/s/y.